Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
Quote | Cynata Therapeutics Ltd (OTCMKTS:CYYNF)
Last: | $0.19 |
---|---|
Change Percent: | 0.0% |
Open: | $0.19 |
Close: | $0.19 |
High: | $0.19 |
Low: | $0.19 |
Volume: | 200 |
Last Trade Date Time: | 06/13/2024 03:00:00 am |
News | Cynata Therapeutics Ltd (OTCMKTS:CYYNF)
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
FDA fails to approve Mesoblast Steroid Refractory Pediatric Graft vs. Host Disease Stem Cell Therapy after FDA advisory board voted 9-1 recommending approval. FDA expresses concerns about Mesoblast MSC manufacturing process in its decision to request another placebo-controlled clinica...
Message Board Posts | Cynata Therapeutics Ltd (OTCMKTS:CYYNF)
Subject | By | Source | When |
---|---|---|---|
http://www.cynata.com | morokoy | investorshub | 05/06/2019 10:28:50 PM |
https://stockhead.com.au/health/dr-borehams-crucible-is-cynata-therapeutics-fuji | morokoy | investorshub | 05/06/2019 10:28:00 PM |